SXTP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SXTP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
60 Degrees Pharmaceuticals's ROE % for the quarter that ended in Jun. 2024 was -326.17%. 60 Degrees Pharmaceuticals's PB Ratio for the quarter that ended in Jun. 2024 was N/A. 60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was N/A.
The historical data trend for 60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
ROE % Adjusted to Book Value | - | - | - | - |
60 Degrees Pharmaceuticals Quarterly Data | |||||||||||||
Dec20 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
ROE % Adjusted to Book Value | Get a 7-Day Free Trial | - | Negative Equity | - | - | - |
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value falls into.
60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as
60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cheryl Xu | director | 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036 |
Geoffrey S Dow | director, 10 percent owner, officer: CEO and President | 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036 |
Charles W Allen | director | 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209 |
Kentucky Technology Inc. | 10 percent owner | 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511 |
Paul Field | director | 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036 |
Tyrone Miller | officer: Chief Financial Officer | 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036 |
Florida State University Research Foundation Inc. | 10 percent owner | 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310 |
Bryan Lee Smith | officer: Chief Medical Officer | 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036 |
Stephen Toovey | director | 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036 |
From GuruFocus
By Marketwired • 10-19-2023
By Marketwired • 05-30-2024
By Marketwired • 08-14-2024
By Marketwired • 09-18-2023
By Marketwired • 06-27-2024
By Marketwired • 09-06-2023
By Marketwired • 09-04-2024
By Marketwired • 08-30-2023
By Marketwired • 06-11-2024
By Marketwired • 07-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.